A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy

被引：40

作者：

Alvarez-Rueda, Nidia ^{[1
]}

Ladjemi, Maha Zohra ^{[1
]}

Behar, Ghislaine ^{[2
]}

Corgnac, Stephanie ^{[1
]}

Pugniere, Martine ^{[3
]}

Roquet, Francoise ^{[3
]}

Bascoul-Mollevi, Caroline ^{[4
]}

Baty, Daniel ^{[5
]}

Pelegrin, Andre ^{[1
]}

Navarro-Teulon, Isabelle ^{[1
]}

机构：

[1] Univ Montpellier I, INSERM, U896, CRLC Val Aurelle Paul Lamarque,IRCM, F-34298 Montpellier 5, France

[2] CNRS, UMR 6204, Unite Biotechnol Biocatalyse & Bioregulat, F-44322 Nantes, France

[3] Ctr Etud Agents Pathogenes & Biotechnol Sante Pha, CNRS, UMR 5236, UM1,UM2, F-34093 Montpellier, France

[4] CRLC Val Aurelle Paul Lamarque, Unite Biostat, F-34298 Montpellier, France

[5] CNRS, UPR 9027, GDR 2352, Lab Ingn Syst Macromol, F-13402 Marseille, France

来源：

VACCINE | 2009年 / 27卷 / 35期

关键词：

Llama antibodies; HER2; Anti-idiotypic vaccine; EPITHELIAL OVARIAN-CANCER; METASTATIC BREAST-CANCER; ANTITUMOR PROPERTIES; MONOCLONAL-ANTIBODY; HER-2/NEU; ANTIGEN; TRASTUZUMAB; PEPTIDE; PROTEIN; HERCEPTIN((R));

D O I：

10.1016/j.vaccine.2009.05.067

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

HER2 over-expression in breast cancer correlates with reduced survival. Anti-idiotypic antibodies (Abs) that closely mimic HER2 could play a crucial role in the development of effective therapeutic vaccines. Here, we show that an anti-idiotypic single domain antibody (sdAb) 1HE isolated from a library generated from a Trastuzumab F(ab')(2)-immunized llama, closely mimics HER2. SdAb 1HE shows high affinity for Trastuzumab F(ab')(2), selectively inhibits HER2 binding to Trastuzumab F(ab')(2), and sera from sdAb 1HE-immunized BALB/c mice contain anti-HER2 antibodies that inhibit viability of HER2-positive cells. These results indicate that sdAb 1HE could be used as an anti-idiotype-based vaccine to boost immunity in patients bearing HER2-positive tumours. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：4826 / 4833

页数：8

共 41 条

[1]

Binding activities and antitumor properties of a new Mouse/Human chimeric antibody specific for GD2 ganglioside antigen [J].

Alvarez-Rueda, Nidia ;

Leprieur, Stephanie ;

Clemenceau, Beatrice ;

Supiot, Stephane ;

Sebille-Rivain, Veronique ;

Faivre-Chauvet, Alain ;

Davodeau, Francois ;

Paris, Francois ;

Barbet, Jacques ;

Aubry, Jacques ;

Birkle, Stephane .

CLINICAL CANCER RESEARCH, 2007, 13 (18) :5613S-5620S

[2]

[Anonymous], CLIN ADV HEMATOL S10

[3]

Phase I and II clinical trials of trastuzumab [J].

Baselga, J .

ANNALS OF ONCOLOGY, 2001, 12 :49-55

[4]

Isolation and characterization of anti-FcγRIII (CD16) llama single-domain antibodies that activate natural killer cells [J].

Behar, Ghislaine ;

Siberil, Sophie ;

Groulet, Agnes ;

Chames, Patrick ;

Pugniere, Martine ;

Boix, Charlotte ;

Sautes-Fridman, Catherine ;

Teillaud, Jean-Luc ;

Baty, Daniel .

PROTEIN ENGINEERING DESIGN & SELECTION, 2008, 21 (01) :1-10

[5]

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study [J].

Bengala, C ;

Zamagni, C ;

Pedrazzoli, P ;

Matteucci, P ;

Ballestrero, A ;

Da Prada, G ;

Martino, M ;

Rosti, G ;

Danova, M ;

Bregni, M ;

Jovic, G ;

Guarneri, V ;

Maur, M ;

Conte, PF .

BRITISH JOURNAL OF CANCER, 2006, 94 (07) :1016-1020

[6]

BERCHUCK A, 1990, CANCER RES, V50, P4087

[7]

Anti-idiotype antibody vaccine therapy for cancer [J].

Bhattacharya-Chatterjee, M ;

Chatterjee, SK ;

Foon, KA .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (08) :869-881

[8]

Multiple sequence alignment with the Clustal series of programs [J].

Chenna, R ;

Sugawara, H ;

Koike, T ;

Lopez, R ;

Gibson, TJ ;

Higgins, DG ;

Thompson, JD .

NUCLEIC ACIDS RESEARCH, 2003, 31 (13) :3497-3500

[9]

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J].

Cho, HS ;

Mason, K ;

Ramyar, KX ;

Stanley, AM ;

Gabelli, SB ;

Denney, DW ;

Leahy, DJ .

NATURE, 2003, 421 (6924) :756-760

[10]

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

← 1 2 3 4 5 →